Want to see GB:RUA full AI Analyst Report?
Top Page
RUA Life Sciences
(LSE:RUA)
Select Model
Select Model
Rating:56Neutral
Price Target:
31.00 p
▲(8.77% Upside)
Action:Reiterated
Date:09/26/26
The score is held back primarily by weak financial performance quality—ongoing operating losses and continued negative operating/free cash flow—despite improving results and a low-leverage balance sheet. Technical trends are supportive (price above major moving averages and positive MACD), but valuation remains challenged given negative earnings and no dividend data.
Positive Factors
Specialized biomaterials platform
The company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.
Negative Factors
Operating losses persist
Operating profitability has not yet been established, so strong gross margin is not currently translating into sustainable earnings after operating costs. Continued EBIT losses could restrict internal funding, delay shareholder returns, and leave results sensitive to the timing of customer-program progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized biomaterials platform
The company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.
Read all positive factors
RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£17.69M
Dividend YieldN/A
Average Volume (3M)163.27K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees59
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume237,126
30 Day Avg. Volume163,266
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RUA Life Sciences Business Overview & Revenue Model
Company Description
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's ...
How the Company Makes Money
RUA Life Sciences generates revenue primarily by supplying biomaterials and related services to medical device companies and other healthcare manufacturers. Key revenue streams include: (1) Biomaterials sales: selling proprietary or specialized me...
RUA Life Sciences Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.46M | 4.11M | 2.19M | 2.18M | 1.63M |
| Gross Profit | 3.06M | 3.17M | 1.72M | 1.43M | 1.04M |
| EBITDA | -383.33K | 401.00K | -1.57M | -1.95M | -2.04M |
| Net Income | -145.33K | 1.00K | -1.44M | -2.00M | -2.07M |
Balance Sheet | |||||
| Total Assets | 9.12M | 9.26M | 8.17M | 5.66M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 3.57M | 3.93M | 1.48M | 2.96M |
| Total Debt | 794.00K | 1.03M | 389.00K | 475.00K | 344.00K |
| Total Liabilities | 1.89M | 1.86M | 987.00K | 980.00K | 1.04M |
| Stockholders Equity | 7.14M | 7.30M | 7.18M | 4.68M | 6.58M |
Cash Flow | |||||
| Free Cash Flow | -298.00K | -281.00K | -1.38M | -1.62M | -3.27M |
| Operating Cash Flow | -137.00K | -219.00K | -1.33M | -1.17M | -2.36M |
| Investing Cash Flow | -59.00K | 70.00K | -85.00K | -449.00K | -904.00K |
| Financing Cash Flow | -459.00K | -196.00K | 3.89M | 132.00K | -66.00K |
RUA Life Sciences Technical Analysis
Positive
28.50
Price Trends
26.78
Positive
23.72
Positive
19.36
Positive
Market Momentum
0.60
Positive
54.53
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 28.5 is above the 20-day moving average (MA) of 28.15, above the 50-day MA of 26.78, and above the 200-day MA of 19.36, indicating a bullish trend. The MACD of 0.60 indicates Positive momentum. The RSI at 54.53 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.
RUA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £17.69M | -123.91 | -2.03% | ― | ― | ― | |
56 Neutral | £16.59M | -15.95 | -6.49% | 1.56% | 24.30% | 93.53% | |
55 Neutral | £3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £18.87M | -1.08 | -1044.57% | ― | 65.60% | 74.84% | |
47 Neutral | £6.04M | -1.41 | -77.85% | ― | 11.90% | -2864.29% | |
43 Neutral | £43.34M | -2.13 | -38.29% | ― | ― | ― |
* Healthcare Sector Average
GB:RUA
RUA Life Sciences
28.50
17.00
147.83%
GB:CREO
Creo Medical
9.65
-2.10
-17.87%
GB:GDR
Genedrive
1.18
0.94
406.47%
GB:IHC
Inspiration Healthcare
18.50
-3.50
-15.91%
GB:OPTI
OptiBiotix Health
5.85
-4.90
-45.58%
GB:SUN
Surgical Innovations
0.40
-0.18
-31.03%
RUA Life Sciences Corporate Events
Business Operations and StrategyFinancial Disclosures
RUA Life Sciences Narrows Losses as Core Manufacturing Turns Profitable and Spin-Out Strategy Takes Shape
Positive
Jun 30, 2026
RUA Life Sciences reported interim results for the six months to 31 March 2026 showing a sharp narrowing of losses as it consolidates its shift toward profitable contract manufacturing and biomaterials licensing. Group revenue rose 6.1% to £2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.